Finally An Osteoporosis Prescription That Will Help Inhibit Bone Loss
Amgen NASDAQ: AMGN pharmaceutical company just released information stating outstanding performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.
Trial reached primary endpoint of Diminishing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, ” I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients.”
Denosumab is the first fully human monoclonal antibody in late stage clinical development that particularly targets RANK Ligand, an essential regulator of osteoclasts the cells that break down bone). Denosumab is being considered for its potential to inhibit all stages of osteoclast activity through a targeted mechanism. Denosumab is being researched for a variety of bone loss conditions such as, postmenopausal osteoporosis, rheumatoid arthritis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to delay bone metastases and stop and treat bone destruction across many stages of cancer.
Osteoporosis is often referred to as the “silent epidemic”, osteoporosis is a world wide problem illness, which is growing in significance as the world population both increases and ages. WHO, The World Health Organization has recently claimed osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this terrible disease.
According to Amgen the economic burden of osteoporosis is referred to as the “silent epidemi’ to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).
Pharmacist-clinical have been researching prescriptions drugs to help patient that have serious side effects. These products are developed almost at the same time as the medications that aid in the treatment of the initial illness. The fact that research is available to help predict the possible effects and interactions drugs have with each other is outstanding.
These medicines are prescribed to prevent and treat osteoporosis. A few prescriptions increase bone thickness or slow the rate of bone loss. Even small amounts of new bone growth can reduce the danger of breaking bones. It is important that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions.
- CF Thompson
